ISA 2022 | The potential of AT-02 as a therapeutic strategy in ATTR & AL amyloidosis
Jonathan Wall, PhD, University of Tennessee Graduate School of Medicine, Knoxville, TN, outlines the mechanism of action of AT-02, an IgG1-peptide fusion that can bind and promote phagocytosis of all forms of amyloid, and emphasizes the importance of removing the amyloid deposits directly from affected tissues and organs to improve the organ function, quality of life (QoL), and overall survival (OS) of patients with amyloidosis. Prof. Wall also states that this agent will be tested in a Phase I study. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Co-founder and shareholder in Attralus Inc. Inventor and patent holder related to amyloid-binding peptide technologies and amyloid-reactive antibody. Receive research funding from Attralus Inc.
